Heplisav-B与卫生保健工作者标准乙型肝炎疫苗增强剂。

IF 5.1 2区医学 Q1 MEDICINE, GENERAL & INTERNAL

Annals of Family Medicine Pub Date : 2025-03-24 DOI:10.1370/afm.240184

Alan L Williams, Raquelle S Newman

{"title":"Heplisav-B与卫生保健工作者标准乙型肝炎疫苗增强剂。","authors":"Alan L Williams, Raquelle S Newman","doi":"10.1370/afm.240184","DOIUrl":null,"url":null,"abstract":"Confidence in hepatitis B seroprotection for US health care workers includes a complete immunization series followed by a hepatitis B surface antigen antibody (anti-HBs) titer ≥10 mIU/mL. We compared standard hepatitis B vaccines to Heplisav-B (Dynavax Technologies Corp) as a single booster for young, healthy, previously vaccinated individuals. Participants (N = 242) had documentation of a single vaccination series and an anti-HBs titer <10 mIU/mL. In this cohort, 1 booster achieved seropositivity for 92.7% (95% CI, 84.8%-97.2%) of the standard hepatitis B vaccine group and 99.4% (95% CI, 96.6%-100.0%) of the Heplisav-B group. Both boosters are likely to produce seropositivity in this population.","PeriodicalId":50973,"journal":{"name":"Annals of Family Medicine","volume":"23 2","pages":"162-164"},"PeriodicalIF":5.1000,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11936371/pdf/","citationCount":"0","resultStr":"{\"title\":\"Heplisav-B vs Standard Hepatitis B Vaccine Booster for Health Care Workers.\",\"authors\":\"Alan L Williams, Raquelle S Newman\",\"doi\":\"10.1370/afm.240184\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Confidence in hepatitis B seroprotection for US health care workers includes a complete immunization series followed by a hepatitis B surface antigen antibody (anti-HBs) titer ≥10 mIU/mL. We compared standard hepatitis B vaccines to Heplisav-B (Dynavax Technologies Corp) as a single booster for young, healthy, previously vaccinated individuals. Participants (N = 242) had documentation of a single vaccination series and an anti-HBs titer <10 mIU/mL. In this cohort, 1 booster achieved seropositivity for 92.7% (95% CI, 84.8%-97.2%) of the standard hepatitis B vaccine group and 99.4% (95% CI, 96.6%-100.0%) of the Heplisav-B group. Both boosters are likely to produce seropositivity in this population.\",\"PeriodicalId\":50973,\"journal\":{\"name\":\"Annals of Family Medicine\",\"volume\":\"23 2\",\"pages\":\"162-164\"},\"PeriodicalIF\":5.1000,\"publicationDate\":\"2025-03-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11936371/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Family Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1370/afm.240184\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Family Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1370/afm.240184","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

摘要

美国卫生保健工作者对乙型肝炎血清保护的信心包括完整的免疫系列，随后是乙型肝炎表面抗原抗体（anti-HBs）滴度≥10 mIU/mL。我们比较了标准乙肝疫苗和Heplisav-B （Dynavax技术公司）作为年轻、健康、以前接种过疫苗的个体的单一增强剂。参与者（N = 242）有单一系列疫苗接种记录和抗hbs滴度

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Heplisav-B vs Standard Hepatitis B Vaccine Booster for Health Care Workers.

Confidence in hepatitis B seroprotection for US health care workers includes a complete immunization series followed by a hepatitis B surface antigen antibody (anti-HBs) titer ≥10 mIU/mL. We compared standard hepatitis B vaccines to Heplisav-B (Dynavax Technologies Corp) as a single booster for young, healthy, previously vaccinated individuals. Participants (N = 242) had documentation of a single vaccination series and an anti-HBs titer <10 mIU/mL. In this cohort, 1 booster achieved seropositivity for 92.7% (95% CI, 84.8%-97.2%) of the standard hepatitis B vaccine group and 99.4% (95% CI, 96.6%-100.0%) of the Heplisav-B group. Both boosters are likely to produce seropositivity in this population.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Annals of Family Medicine 医学-医学：内科

CiteScore

3.70

自引率

4.50%

发文量

142

审稿时长

6-12 weeks

期刊介绍： The Annals of Family Medicine is a peer-reviewed research journal to meet the needs of scientists, practitioners, policymakers, and the patients and communities they serve.